SCHEMBL5236869

SCHEMBL5236869

CCCCOc1c(CNC(=O)OC(C)(C)C)n(CC(C)C)c(=O)c2ccc(C(=O)OC)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
CYP2C19 P33261 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
DPP4 P27487 10/20 0.37
KDM4E B2RXH2 5/20 0.37
GAA P10253 3/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
GLA P06280 1/20 0.36
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
CYP1A1 P04798 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2B6 P20813 1/20 0.35
CYP3A43 Q9HB55 1/20 0.35
TP53 P04637 1/20 0.35
BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5231264 0.92 DPP4 (0.46) ALDH1A1CYP2C19DPP4KDM4EGAA
SCHEMBL5237159 0.91 DPP4 (0.47) CYP2C19DPP4CYP1A1CYP2D6CYP2B6
SCHEMBL5234879 0.90 KDM4E (0.38) ALDH1A1CYP2C19CYP1A2CYP2C9KDM4E
SCHEMBL5238626 0.87 KDM4E (0.36) ALDH1A1CYP2C19CYP1A2CYP2C9KDM4E
SCHEMBL5235263 0.87 DPP4 (0.40) ALDH1A1CYP2C19CYP1A2CYP2C9DPP4
SCHEMBL27581829 0.86 TSHR (0.41) ALDH1A1DPP4HSD17B10HTTTP53
SCHEMBL5238826 0.85 SDCBP (0.35) CYP2C19DPP4CYP1A1CYP2D6CYP2B6
SCHEMBL5238822 0.83 DPP4 (0.43) ALDH1A1CYP2C19DPP4KDM4EHPGD
SCHEMBL5238832 0.83 DPP4 (0.43) ALDH1A1CYP2C19DPP4KDM4EHPGD
SCHEMBL28751772 0.83 CYP1A1 (0.34) CYP2C19DPP4CYP1A1CYP2D6CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
CN-1500080-A Fused heterocyclic compounds ����ҩƷ��ҵ��ʽ���� 2004-05-26 CN disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 ALDH1A1 387/4885CYP2C19 1652/4885CYP1A2 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.